Randomized head-to-head trial of proton pump inhibitor (PPI) vs topical corticosteroids (TCs) post food bolus impaction and/or for untreated patients with Eosinophilic esophagitis (EoE).
- Conditions
- Eosinophilic oesophagitis (EoE)Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
- Registration Number
- ACTRN12623000604606
- Lead Sponsor
- orthern Adelaide Local Health Network
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 72
Patients who present with a food bolus obstruction (FBO) or dysphagia.
Diagnosed with EoE, which is defined as eosophageal biopsy containing >15 eosinophils per high power field, in any one oesophageal location (peak count).
On nil current treatment, or willing to cease treatment with PPI or diet for 8 weeks prior to repeat endoscopy.
Exclusion criteria will comprise any of the following conditions or factors:
•Coexistent medical conditions that could cause oesophageal eosinophilia (e.g. primary hypereosinophilic syndrome, organ transplant recipient, connective tissue disorder, Crohn’s disease)
•Medications that could cause oesophageal eosinophilia (e.g. antiepileptic, clozapine)
•Medications that could suppress the immune system and decrease eosinophil count (e.g,systemic corticosteroids, immunosuppressant such as methotrexate or azathioprine, biological agents such as anti – TNF)
•Usual residence is a forensic facility
•Intellectual disability
•Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method